EBBINGHAUS primary results provide a first indication as to whether the addition of evolocumab to statin therapy affects cognitive function over time in patients with stable CVD already receiving moderate- to high-intensity statin therapy.

Keywords: ACC17, ACC Annual Scientific Session, Antibodies, Monoclonal, Cognition, Dementia, Double-Blind Method, Executive Function, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Lipoproteins, LDL, Memory, Short-Term, Middle Aged, Nervous System Diseases, Neuropsychological Tests, Primary Prevention, Reaction Time, Receptors, LDL, Risk Factors, Stroke

< Back to Listings